Six years later: Too risky in Parkinson's disease

Prescrire International

Volumn 11, Issue 60, 2002, Pages 108-111

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANTIPARKINSON AGENT; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; CARBIDOPA PLUS LEVODOPA; DOPA DECARBOXYLASE INHIBITOR; FLUOXETINE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; NARATRIPTAN; PAROXETINE; PETHIDINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SUMATRIPTAN; TOCOPHEROL; TRAMADOL; ZOLMITRIPTAN; MONOAMINE OXIDASE INHIBITOR;

AGITATION; ARTICLE; BRADYKINESIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFUSION; DEPRESSION; DOSE RESPONSE; DRUG FATALITY; DRUG INDICATION; DRUG MARKETING; EPIDEMIOLOGICAL DATA; FRANCE; GAIT DISORDER; HALLUCINATION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MORTALITY; MOTOR DYSFUNCTION; NAUSEA; NEUROLOGIC DISEASE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRESCRIPTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYNCOPE; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG COMBINATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANTIPARKINSON AGENTS; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FRANCE; HUMANS; LEVODOPA; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; SELEGILINE; TREATMENT OUTCOME;

EID: 0036676206     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Prescrire Rédaction "sélégiline-Eldéprineo" Rev Prescr 1989; 9 (85): 186-187.
2. "Prescrire Editorial Staff "Selegiline" Prescr Int 1996; 5 (25): 140-142.
3. The Parkinson Study Group "Effect of Deprenyl on the progression of disability in early Parkinson's disease" N Engl J Med 1989; 321 (20): 1364-1371.
4. Parkinson Study Group "Impact of Deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa" Ann Neurol 1996; 39 (1): 29-36.
5. Parkinson Study Group "Impact of Deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa" Ann Neurol 1996; 39 (1): 37-45.
6. Myllylä VV et al. "Selegiline as initial treatment in de novo parkinsonian patients" Neurology 1992; 42: 339-343.
7. Myllylä VV et al. "Selegiline as the primary treatment of Parkinson's disease - A long-term double-blind study" Acta Neurol Scand 1997; 95: 211-218.
8. Pålhagen S et al. "Selegiline delays the onset of disability in de novo parkinsonian patients" Neurology 1998; 51: 520-525.
9. Lees AJ et al. "Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease" BMJ 1995; 311: 1602-1607.
10. "Effect of adding selegiline to levodopa in early, mild Parkinson's disease" (letters) BMJ 1996; 312: 702-705.
11. Mizuno Y and Kondo T "Mortality associated with selegiline in Parkinson's disease - What do the available data mean?" Drug Saf 1997; 16 (5): 289-294.
12. Ben-Shlomo Y et al. "Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry" BMJ 1998; 316: 1191-1196.
13. Przuntek H et al. "SELEDO: a 5-year long-term trial on the effect of selegiline in early parkinsonian patients treated with levodopa" Eur J Neurol 1999; 6 (2): 141-150.
14. Larsen JP et al. "Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study" Eur J Neurol 1999; 6 (5): 539-547.
15. Thorogood M et al. "Mortality in people taking selegiline: observational study" BMJ 1998; 317: 252-254.
16. "Eldeprylo". In: "The Physicians' Desk Reference" 55th ed, Medical Economics Company, Montvale 2001: 3162-3164.
17. Turkka J et al. "Selegiline diminishes cardiovascular autonomic responses in Parkinson's disease" Neurology 1997; 48: 662-667.
18. Churchyard A et al. "Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease" J Neurol Neurosurg Psychiatry 1997: 63: 228-234.
19. Churchyard A et al. "Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal" Mov Disord 1999; 14 (2): 246-251.
20. Montastruc JL et al. "Adverse drug reactions to selegiline: a review of the french pharmacovigilance database" Clin Neuropharmacol 2000; 23 (5): 271-275.
21. French agency for health product safety "Résumé des caractéristiques du produit - Deprenyl 5 mg" 3 March 1999: 5 pages.
22. French agency for health product safety "Résumé des caractéristiques du produit - Deprenyl 5 mg" 12 June 2001: 6 pages.
23. French datasheet compendium "Interactions médicamenteuses" Vidal, Paris 2002: 69.
24. Prescrire Editorial Staff "Drug interactions with selective serotonin reuptake inbibitors" Prescr Int 2001; 10 (51): 25-31.
25. Heinonen EH and Myllylä V "Safety of selegiline (Deprenyl) in the treatment of Parkinson's disease" Drug Saf 1998; 19 (1): 11-22.
26. French agency for health product safety "Résumé des caractéristiques du produit - Deprenyl 5 mg" 28 March 1997: 8 pages.
27. Lees AJ et al. "Ten-year follow-up of three different initial treatments in de-novo PD - A randomized trial" Neurology 2001; 57: 1687-1694.
28. Parkinson Study Group "Mortality in DATATOP: a multicenter trial in early Parkinson's disease" Ann Neurol 1998; 43 (3):